Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Collegium Pharmaceutical (COLL) over the last 7 years, with Q3 2025 value amounting to $1.3 million.

  • Collegium Pharmaceutical's Amortization of Deferred Charges rose 1117.55% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 1626.24%. This contributed to the annual value of $6.0 million for FY2024, which is 3033.01% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Amortization of Deferred Charges stood at $1.3 million for Q3 2025, which was up 1117.55% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Amortization of Deferred Charges peaked at $2.5 million during Q2 2022, and registered a low of $779000.0 during Q4 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median Amortization of Deferred Charges value was $1.4 million (recorded in 2024), while the average stood at $1.6 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Amortization of Deferred Charges tumbled by 6939.1% in 2021 and then soared by 20590.5% in 2022.
  • Collegium Pharmaceutical's Amortization of Deferred Charges (Quarter) stood at $779000.0 in 2021, then soared by 205.91% to $2.4 million in 2022, then dropped by 17.62% to $2.0 million in 2023, then decreased by 27.46% to $1.4 million in 2024, then decreased by 5.69% to $1.3 million in 2025.
  • Its Amortization of Deferred Charges stands at $1.3 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.